<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042796</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01873</org_study_id>
    <secondary_id>ADVL0114</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <secondary_id>CDR0000069471</secondary_id>
    <nct_id>NCT00042796</nct_id>
  </id_info>
  <brief_title>Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase I Study Of Decitabine (DAC) (IND # 50733) In Children With Relapsed Or Refractory Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop&#xD;
      growing or die. This phase I trial is studying the side effects and best dose of decitabine&#xD;
      in treating children with relapsed or refractory acute myeloid leukemia or acute&#xD;
      lymphoblastic leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of decitabine that is associated with consistent&#xD;
      evidence of deoxyribonucleic acid (DNA) demethylation in children with relapsed or refractory&#xD;
      acute myeloid leukemia or acute lymphoblastic leukemia.&#xD;
&#xD;
      II. Determine the dose-limiting toxicity, pharmacokinetics, and antitumor activity of this&#xD;
      drug in these patients.&#xD;
&#xD;
      III. Determine the biologic correlates of decitabine-induced DNA demethylation by&#xD;
      characterizing, before and after treatment, global and specific DNA methylation status (using&#xD;
      methylation microarrays) and hemoglobin F levels in these patients.&#xD;
&#xD;
      IV. Determine the biologic correlates of decitabine-induced DNA demethylation by&#xD;
      characterizing, before and after treatment, global changes in gene expression profiles using&#xD;
      cDNA microarrays and drug sensitivity of blast cells by MTT assays in these patients.&#xD;
&#xD;
      V. Determine the biologic correlates of decitabine-induced DNA demethylation by&#xD;
      characterizing, before and after treatment, deletions and single nucleotide polymorphisms in&#xD;
      genomic DNA of deoxycytidine kinase and cytidine deaminase genes in these patients.&#xD;
&#xD;
      VI. Determine the biologic correlates of decitabine-induced DNA demethylation by&#xD;
      characterizing, before and after treatment, acetylation and methylation of histones H3 and H4&#xD;
      and helicase protein expression in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to&#xD;
      disease type (acute myeloid leukemia vs acute lymphoblastic leukemia).&#xD;
&#xD;
      Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6&#xD;
      weeks for a minimum of 4 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of decitabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-21 patients will be accrued for this study within 7.5-21&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>December 2002</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the highest dose at which fewer than one-third of patients experience DLT assessed using CTC version 2.0</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be estimated by proportions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be estimated by proportions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA methylation</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Pearson correlation will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profiles</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be analyzed using hierarchical clustering.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDAC/HAT activity</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Pearson correlation coefficient analysis will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of mutant helicases</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Childhood Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Childhood Acute Promyelocytic Leukemia (M3)</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (decitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (decitabine)</arm_group_label>
    <other_name>5-aza-dCyd</other_name>
    <other_name>5AZA</other_name>
    <other_name>DAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (decitabine)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (decitabine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed acute myeloid leukemia (AML) or acute lymphoblastic leukemia&#xD;
             that is considered refractory to conventional therapy or for which no conventional&#xD;
             therapy exists&#xD;
&#xD;
          -  For patients with AML:&#xD;
&#xD;
               -  M3 marrow&#xD;
&#xD;
               -  M2 marrow with at least 15% blasts&#xD;
&#xD;
               -  Secondary AML allowed&#xD;
&#xD;
          -  CNS involvement allowed&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (age 17 to 21)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (age 16 and under)&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  WBC no greater than 30,000/mm^3&#xD;
&#xD;
          -  Patients with granulocytopenia, anemia, and/or thrombocytopenia are eligible but are&#xD;
             not evaluable for hematological toxicity&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  ALT no greater than 5 times normal&#xD;
&#xD;
          -  Albumin at least 2 g/dL&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate at least lower limit&#xD;
             of normal&#xD;
&#xD;
          -  Shortening fraction at least 27% by echocardiogram&#xD;
&#xD;
          -  Ejection fraction at least 50% by MUGA scan&#xD;
&#xD;
          -  No evidence of dyspnea at rest&#xD;
&#xD;
          -  No exercise intolerance&#xD;
&#xD;
          -  Oxygen saturation greater than 94% by pulse oximetry&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Concurrent seizure disorder allowed if well controlled on anticonvulsants&#xD;
&#xD;
          -  No grade 2 or greater CNS toxicity&#xD;
&#xD;
          -  No uncontrolled infection (i.e., infections associated with fever, dissemination,&#xD;
             hemodynamic instability [requiring pressor support], and progression while on therapy)&#xD;
&#xD;
          -  No active graft-versus-host disease (GVHD)&#xD;
&#xD;
               -  GVHD well controlled on cyclosporine allowed&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 1 week since prior biologic agents&#xD;
&#xD;
          -  At least 6 months since prior allogeneic bone marrow transplantation (BMT)&#xD;
&#xD;
          -  At least 3 months since prior autologous BMT&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) during the first course of therapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior cytarabine&#xD;
&#xD;
          -  At least 24 hours since prior cytoreductive therapy with hydroxyurea (20-30 mg/kg/day&#xD;
             for no more than 7 days) to lower the WBC to no greater than 30,000/mm^3&#xD;
&#xD;
          -  No concurrent intrathecal therapy during the first course of decitabine&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 weeks since prior cranial or craniospinal radiotherapy&#xD;
&#xD;
          -  No concurrent medications that induce cytidine deaminase or deoxycytidine kinase&#xD;
             (e.g., cytarabine)&#xD;
&#xD;
          -  No concurrent medications that mask poor or deteriorating organ function&#xD;
&#xD;
          -  No concurrent CNS prophylaxis during the first course of decitabine&#xD;
&#xD;
          -  Concurrent anticonvulsants with no known interactions with decitabine allowed&#xD;
&#xD;
          -  Concurrent antibacterial or antifungal therapies for controlled infections allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Lacayo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

